Shares of Opko Health, Inc. (NASDAQ:OPK) have moved -31.40% so far in 2017 and they are now -33.61% from where the price during the same period last year.
Over the past six months the shares price has moved -41.63%, while it has moved -19.75% over the previous quarter. Over the last week and the past one month, the shares price has moved -4.92% and -8.86%, respectively.
The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
Recently, Opko Health, Inc. (NASDAQ:OPK) stated that studying the technical demonstrates its 20-Day Simple Moving Average is $-2.16% and 50-Day Simple Moving Average is $-11.10% while 200-Day Simple Moving Average is $-28.66%.
The stock has dropped to a low of $6.51% over the previous 50 days and made a high of $-22.76% over the same period. Though, the stock’s price range in the previous 12 months is a high of $-47.49% and a low of $6.51%.
Analysts following Opko Health, Inc. have a mean recommendation of 1.80 on its stock. Recommendation of 1 indicates STRONG BUY, 3 shows HOLD and 5 indicates SELL.
The stock is trading around $6.38, but it should be trading around $13.50 by the close of the next 12 months as per the analysts.
The equity’s average volume, which is the mean of three months, is 4.29M, while its relative volume is 0.79.
Insiders own 6.80% of Opko Health, Inc., while institutional investors hold 23.80% of the company.
Of the firm’s 557.60M shares due, 336.53M are free float. Of the floating shares, 21.88% are sold short, which brings short ratio to 17.17.
Opko Health, Inc. posted EPS for the preceding fiscal year and the ongoing year’s EPS is projected to increase 26.00% over the previous year’s EPS.
OPKO Health, Inc. (NASDAQ:OPK) announces it has entered into agreements with several large Medicare Part D plan sponsors, including the largest Medicare Part D plan, and additional commercial insurance plans for reimbursement of RAYALDEE(R) (extended-release calcifediol), which expands the percentage of insured lives with access to RAYALDEE to approximately 68% as of June 1, 2017.